Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America
ESMO Open · 2026-07 · 11 (7) · 108243
DOI: 10.1016/j.esmoop.2026.108243 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESMO Open, 2026-07. Verfasst von L Hart und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Wake Forest University School of Medicine, Winston-Salem, USA. Electronic address: llhart@flcancer.com. Hauptthemen laut MEDLINE: Aminopyridines, Purines, Breast Neoplasms, Aromatase Inhibitors. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Medicine, Wake Forest University School of Medicine, Winston-Salem, USA. Electronic address: llhart@flcancer.com.
- Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA.
- Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, USA.
- Breast Oncology Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Illinois College of Medicine and University of Illinois Cancer Center, Chicago, USA.
- KREDHERA, LLC, Hampton, USA.
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Hart, L., Rugo, H. S., Sharma, P., Sammons, S., Gadi, V. K., Mavros, P., Kaur, M., Boualam, N., Keane, C., Sopher, G., Pathak, P., & Tarantino, P. (2026). Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America. ESMO Open, 11(7), 108243. https://doi.org/10.1016/j.esmoop.2026.108243
Vancouver
Hart L, Rugo HS, Sharma P, Sammons S, Gadi VK, Mavros P, et al. Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America. ESMO Open. 2026;11(7):108243. doi:10.1016/j.esmoop.2026.108243
BibTeX
@article{Hart2026,
author = {Hart, L and Rugo, H S and Sharma, P and Sammons, S and Gadi, V K and Mavros, P and Kaur, M and Boualam, N and Keane, C and Sopher, G and Pathak, P and Tarantino, P},
title = {Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America},
journal = {ESMO Open},
year = {2026},
volume = {11},
number = {7},
pages = {108243},
doi = {10.1016/j.esmoop.2026.108243}
}
EUVIMED